181 related articles for article (PubMed ID: 36922934)
21. Synergistic anti-pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf-3 protein and peripheral blood mononuclear cells.
Uchida D; Shiraha H; Kato H; Sawahara H; Nagahara T; Iwamuro M; Kataoka J; Horiguchi S; Watanabe M; Takaki A; Nouso K; Nasu Y; Kumon H; Yamamoto K
J Gastroenterol Hepatol; 2016 Jun; 31(6):1154-9. PubMed ID: 26643412
[TBL] [Abstract][Full Text] [Related]
22. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
23. R-spondin-3 promotes proliferation and invasion of breast cancer cells independently of Wnt signaling.
Ter Steege EJ; Doornbos LW; Haughton PD; van Diest PJ; Hilkens J; Derksen PWB; Bakker ERM
Cancer Lett; 2023 Aug; 568():216301. PubMed ID: 37406727
[TBL] [Abstract][Full Text] [Related]
24. Evidence for tankyrases as antineoplastic targets in lung cancer.
Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ
BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985
[TBL] [Abstract][Full Text] [Related]
25. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
Spreafico A; Tentler JJ; Pitts TM; Tan AC; Gregory MA; Arcaroli JJ; Klauck PJ; McManus MC; Hansen RJ; Kim J; Micel LN; Selby HM; Newton TP; McPhillips KL; Gustafson DL; Degregori JV; Messersmith WA; Winn RA; Eckhardt SG
Clin Cancer Res; 2013 Aug; 19(15):4149-62. PubMed ID: 23757356
[TBL] [Abstract][Full Text] [Related]
26. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice.
Tumova L; Pombinho AR; Vojtechova M; Stancikova J; Gradl D; Krausova M; Sloncova E; Horazna M; Kriz V; Machonova O; Jindrich J; Zdrahal Z; Bartunek P; Korinek V
Mol Cancer Ther; 2014 Apr; 13(4):812-22. PubMed ID: 24552772
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer.
Amerizadeh F; Rahmani F; Maftooh M; Nasiri SN; Hassanian SM; Giovannetti E; Moradi-Marjaneh R; Sabbaghzadeh R; Shahidsales S; Joudi-Mashhad M; Ghayour-Mobarhan M; Ferns GA; Khazaei M; Avan A
Tissue Cell; 2022 Aug; 77():101853. PubMed ID: 35803035
[TBL] [Abstract][Full Text] [Related]
28. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
29. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
[TBL] [Abstract][Full Text] [Related]
30. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
31. Wnt addiction of genetically defined cancers reversed by PORCN inhibition.
Madan B; Ke Z; Harmston N; Ho SY; Frois AO; Alam J; Jeyaraj DA; Pendharkar V; Ghosh K; Virshup IH; Manoharan V; Ong EH; Sangthongpitag K; Hill J; Petretto E; Keller TH; Lee MA; Matter A; Virshup DM
Oncogene; 2016 Apr; 35(17):2197-207. PubMed ID: 26257057
[TBL] [Abstract][Full Text] [Related]
32. Nigericin Exerts Anticancer Effects on Human Colorectal Cancer Cells by Inhibiting Wnt/β-catenin Signaling Pathway.
Liu F; Li W; Hua S; Han Y; Xu Z; Wan D; Wang Y; Chen W; Kuang Y; Shi J; Zhi Q
Mol Cancer Ther; 2018 May; 17(5):952-965. PubMed ID: 29483216
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system.
Xu Z; Li J; Wu Y; Sun Z; Luo L; Hu Z; He S; Zheng J; Zhang H; Zhang X
Eur J Med Chem; 2016 Jan; 108():154-165. PubMed ID: 26647303
[TBL] [Abstract][Full Text] [Related]
34. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
35. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
[TBL] [Abstract][Full Text] [Related]
36. VALD-3 inhibits proliferation and induces apoptosis of colorectal cancer cells via upregulating tumor suppressor activity of p53 to inhibit Wnt/β-catenin signal pathway.
Li H; Meng Y; Ma S; Dang C; Xue L
Anticancer Drugs; 2021 Nov; 32(10):1046-1057. PubMed ID: 34419958
[TBL] [Abstract][Full Text] [Related]
37. Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer.
Kleeman SO; Leedham SJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202731
[TBL] [Abstract][Full Text] [Related]
38. C644-0303, a small-molecule inhibitor of the Wnt/β-catenin pathway, suppresses colorectal cancer growth.
Yan Y; Zhang Y; Li M; Zhang Y; Zhang X; Zhang X; Xu Y; Wei W; Wang J; Xu X; Song Q; Zhao C
Cancer Sci; 2021 Nov; 112(11):4722-4735. PubMed ID: 34431598
[TBL] [Abstract][Full Text] [Related]
39. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
Tam BY; Chiu K; Chung H; Bossard C; Nguyen JD; Creger E; Eastman BW; Mak CC; Ibanez M; Ghias A; Cahiwat J; Do L; Cho S; Nguyen J; Deshmukh V; Stewart J; Chen CW; Barroga C; Dellamary L; Kc SK; Phalen TJ; Hood J; Cha S; Yazici Y
Cancer Lett; 2020 Mar; 473():186-197. PubMed ID: 31560935
[TBL] [Abstract][Full Text] [Related]
40. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
